Eli Lilly: The Buy Case Gets Stronger (Rating Upgrade)

Despite a recent price correction in Eli Lilly (LLY) stock following an outlook downgrade related to acquisition costs, an analyst argues for a buy rating due to strong sales, particularly for Zepbound, attractive market multiples, and the company's defensive characteristics amid market uncertainty. While the oncology segment, where the acquisition was made, showed weakness in Q1 2025, the analyst believes diversification is beneficial given pricing pressures from policy, compounders, and counterfeit products, suggesting potential for an upside price surprise.

Analysis

Eli Lilly's (LLY) stock has experienced a slight price correction, diverging from the S&P 500's recent gains, which is viewed as an over-correction following an outlook downgrade primarily attributed to acquisition-related costs. While the oncology segment, where the acquisition occurred, showed a lackluster performance in Q1 2025, its long-term strategic value for diversification is considered promising. This diversification is particularly pertinent as the company navigates significant downward pricing pressures stemming from policy changes, competition from compounders, and the challenge of counterfeit products. Despite these headwinds, Eli Lilly demonstrates considerable strength in its sales, especially for its Zepbound product, maintains attractive market multiples, and exhibits defensive characteristics that are valuable during periods of market uncertainty, suggesting a potential for an upside price surprise.

Key Decisions for Investors

• Investors could view Eli Lilly's recent stock price correction as a potential entry point, given the strong sales performance of Zepbound, attractive valuation multiples, and the analyst's thesis of an enhanced buy case.
• It is advisable to monitor the oncology segment's integration and long-term contribution to growth and diversification, particularly against the backdrop of its Q1 2025 performance and ongoing industry-wide pricing pressures.
• Consider Eli Lilly's defensive attributes for portfolio construction, especially if anticipating continued market volatility, as these characteristics may offer resilience and potential for outperformance.